Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation

K El-Adl, HM Sakr, RG Yousef, ABM Mehany… - Bioorganic …, 2021 - Elsevier
VEGF/VEGFR2 pathway is the crucial therapeutic target in the treatment of cancer. So that, a
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …
被引用次数：66 相关文章

Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.

K El-Adl, HM Sakr, RG Yousef, ABM Mehany… - Bioorganic …, 2021 - europepmc.org
VEGF/VEGFR2 pathway is the crucial therapeutic target in the treatment of cancer. So that, a
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …

Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation

K El-Adl, HM Sakr, RG Yousef… - Bioorganic …, 2021 - pubmed.ncbi.nlm.nih.gov
VEGF/VEGFR2 pathway is the crucial therapeutic target in the treatment of cancer. So that, a
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …